Assembly Biosciences, Inc.

AI-generated fair value estimate for this company.

Method: Net asset plus risk-adjusted pipeline value: approximately $320M in cash and short-term investments plus a conservative $75M placeholder for near-term Gilead-partnered milestone/royalty value on the HSV helicase-primase program, divided by 20.36M shares outstanding.

Reasoning: Assembly Biosciences is a well-funded but largely pre-commercial biotech whose near-term reported revenue is mostly partner milestone payments rather than product sales, and its HBV asset was recently declined by partner Gilead, so a cash-plus-conservative-pipeline approach was used rather than a standard operating-cash-flow DCF.